Featured Research

from universities, journals, and other organizations

Drug trials funded by industry are more likely to publish favorable results, researchers find

Date:
August 3, 2010
Source:
Children's Hospital Boston
Summary:
When published results are systematically tracked for drug trials registered with ClinicalTrials.gov, those from industry-funded trials are the likeliest to be favorable to the drug in question, researchers report.

When published results are systematically tracked for drug trials registered with ClinicalTrials.gov, those from industry-funded trials are the likeliest to be favorable to the drug in question, report researchers at Children's Hospital Boston.

Related Articles


Publishing in the August 3 issue of the Annals of Internal Medicine, the researchers call for more public disclosure about clinical drug trials at their outset to reduce the possibility of bias in the findings.

The research team, led by Florence Bourgeois, MD, MPH, of Children's Division of Emergency Medicine, and Kenneth Mandl, MD, MPH, Laboratory Director in the Children's Hospital Informatics Program, reviewed 546 drug trials conducted between 2000 and 2006 and listed with ClinicalTrials.gov, a comprehensive, web-based federal registry of clinical trials. The analysis focused on five classes of drugs: cholesterol-lowering drugs, antidepressants, antipsychotics, proton-pump inhibitors and vasodilators. The researchers scanned the medical literature for publications associated with each trial, checking four separate databases and contacting trial investigators directly if necessary.

Overall, allowing for a three-year lag time from the completion of the trial, two-thirds of the trials had published results. The industry-funded trials reported positive outcomes 85 percent of the time, as compared with 50 percent for government-funded trials and 72 percent for trials funded by nonprofits or non-federal organizations. In addition, among the nonprofit/nonfederal trials, those that had industry contributions (nearly half) were more likely than those without to report positive outcomes (85 vs. 61 percent). These differences were all statistically significant.

The researchers acknowledge that the pharmaceutical industry was probably more selective in which trials it funded, helping to account for their greater proportion of favorable outcomes. "Industry is very good at knowing what they want to study, and industry-sponsored studies are more efficient and well funded," says Bourgeois, the study's first author. "But despite these potential biases, this is a stunning result."

The industry-funded trials were in more advanced phases of study; 89 percent were Phase 3 or Phase 4, versus just 51 percent of government-funded trials and 65 percent of nonprofit/nonfederally-funded trials. However, even Phase 1 and 2 trials funded by industry reported the highest percentage of favorable outcomes.

In addition, industry-funded trials were the least likely to have published results within two years of study completion (32 percent) as compared with trials with no industry contributions (54 percent for government trials, and 56 percent for purely nonprofit/nonfederal trials).

As the researchers discuss in the paper, clinical trials can be manipulated in various ways to make the results appear more favorable. Publication bias -- a tendency to selectively publish only positive results of a trial, or delay publication of negative results -- is one factor that has received much attention, as in a well-publicized 2008 study of antidepressants in The New England Journal of Medicine.

"While we cannot specifically point to which factors contribute to the association between funding source and positive result reporting, our findings speak to the need for more disclosure of all elements of a study," says Bourgeois. "Publication bias is likely a contributing factor, but there may be many more, including biases in study design, patient selection, data analysis and results reporting."

The use of registries like ClinicalTrials.gov, launched in 1999, was hoped to reduce publication bias by creating a record for all clinical trials. In addition, in 2005, the International Committee of Medical Journal Editors began requiring that a trial be registered before enrolling patients in order to be considered for publication, thus creating a record of the planned study outcomes before the study's initiation. In 2007, the FDA expanded the scope of ClinicalTrials.gov, requiring the sponsors of all drug, biologic and device trials to register their studies upon launch (phase I trials excepted).

If trial protocols are made public in advance, a trial sponsor is less able to manipulate or selectively publish the findings, the researchers argue. "Our main call is for transparency, to enable better understanding of the impact of funding source on the study outcomes, and for all study results -- good or bad -- to be made available," says Mandl, the study's senior investigator, also an Associate Professor at Harvard Medical School.

The study was funded by the National Library of Medicine and the National Institute of Child Health and Human Development.


Story Source:

The above story is based on materials provided by Children's Hospital Boston. Note: Materials may be edited for content and length.


Cite This Page:

Children's Hospital Boston. "Drug trials funded by industry are more likely to publish favorable results, researchers find." ScienceDaily. ScienceDaily, 3 August 2010. <www.sciencedaily.com/releases/2010/08/100802173713.htm>.
Children's Hospital Boston. (2010, August 3). Drug trials funded by industry are more likely to publish favorable results, researchers find. ScienceDaily. Retrieved October 30, 2014 from www.sciencedaily.com/releases/2010/08/100802173713.htm
Children's Hospital Boston. "Drug trials funded by industry are more likely to publish favorable results, researchers find." ScienceDaily. www.sciencedaily.com/releases/2010/08/100802173713.htm (accessed October 30, 2014).

Share This



More Science & Society News

Thursday, October 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Obama: The US Will Not 'run and Hide' From Ebola

Obama: The US Will Not 'run and Hide' From Ebola

AP (Oct. 29, 2014) Surrounded by health care workers in the White House East Room, President Barack Obama said the U.S. will likely see additional Ebola cases in the weeks ahead. But he said the nation can't seal itself off in the fight against the disease. (Oct. 29) Video provided by AP
Powered by NewsLook.com
Lowe's Testing Robot Sales Assistants in California Store

Lowe's Testing Robot Sales Assistants in California Store

Buzz60 (Oct. 29, 2014) Lowe’s is testing out what it’s describing as a robotic shopping assistant in one of its Orchard Supply Hardware Stores in California. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
States And White House Disagree On Ebola Quarantines

States And White House Disagree On Ebola Quarantines

Newsy (Oct. 29, 2014) Officials in New Jersey and Maine have quarantined Doctors Without Borders nurse Kaci Hickox, a move the White House doesn't seem to support. Video provided by Newsy
Powered by NewsLook.com
New Wave of Online Delivery Gains Momentum

New Wave of Online Delivery Gains Momentum

AFP (Oct. 29, 2014) With start-ups like Postmates offering quick delivery of meals, groceries and other items through a smartphone app, the online world is delivering again. Duration: 01:39 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Science & Society

Business & Industry

Education & Learning

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins